Updates in HER2+ Early and Metastatic Breast Cancer - Episode 4

Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2+ Early Breast Cancer

January 30, 2023

Joyce O’Shaughnessy, MD, Virginia Borges, MD, Maryam Lustberg, MD, MPH, Debu Tripathy, MD

The panel shares the factors that influence whether they recommend a subcutaneous or intravenous formulation of pertuzumab/trastuzumab in addition to chemotherapy.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Incidence and Typical Prognosis of HER2+ Early Breast Cancer

EP. 2: Neoadjuvant Treatment of HER2+ Early Breast Cancer

EP. 3: De-Escalation Approaches in Patients with HER2+ Early Breast Cancer

Now Viewing

EP. 4: Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2+ Early Breast Cancer

EP. 5: Factors Informing Adjuvant Treatment Selection in HER2+ Early Breast Cancer

EP. 6: Expert Perspectives on Clinical Experience with Ado-Trastuzumab Emtansine (T-DM1)

EP. 7: Clinical Data Updates on Adjuvant Pertuzumab/Trastuzumab for HER2+ Early Breast Cancer

EP. 8: Extended Adjuvant Neratinib Therapy for Patients with HER2+ Early Breast Cancer

EP. 9: Data Updates in Adjuvant HER2+ Early Breast Cancer from SABCS 2022

EP. 10: HER2+ mBC: First-Line Treatment Regimens

EP. 11: Second-Line Treatment of HER2+ mBC and Recent Data Updates

EP. 12: Options for Third- and Further-Line Treatment of HER2+ mBC

EP. 13: Use of MRI for Surveillance of Brain Metastases in Patients with HER2+ mBC

EP. 14: Emerging Data and Investigational Agents in HER2+ mBC

EP. 15: Unmet Needs and the Future of HER2+ Breast Cancer Treatment